Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The US has published its final negotiating objectives for a post-Brexit trade deal with the UK, which include pushing for stronger IP protections and changes to UK processes for patient access to new drugs.
Latest From Brexit
Delays in the delivery of medicines with short lead times will be longer than originally expected in the event of a no-deal Brexit, UK health care providers have been warned.
There are six weeks or less for medtech companies to be ready to operate as well as they can under Brexit – assuming that it will take place at the third time of asking. The new NHS procurement scheme, already in place, is another potentially disruptive concept for UK companies to adapt to.
As the Brexit clock continues to tick, industry says it is not impressed by government reassurances that all is well where the continued supply of medicines is concerned.
Life science companies need more information on plans for alternative medicine supply routes if the UK leaves the EU without a deal, according to the BioIndustry Association, which says the release of the Operation Yellowhammer document shows the “significant impact” such an outcome would have on the sector.
If you are finding it difficult to follow what is happening on the broad political level in the UK as well as on the technical medtech level, you are not alone. Here we explain why Brexit-related dates are up in the air for the UK.
Sector wants R&D tax credits updated, investment in Biomedical Catalyst, and is dismayed by spending delay.
The UK government has set 1 November 2019 as the date the UK’s own medtech regulations will apply, the day after the country is, in theory, due to leave the EU and potentially without a deal. But nothing is certain on the UK political scene any longer, not even this.
Draft regulations on medicines and medical devices could get caught up in the chaos that seems about to engulf the UK parliament as opposition MPs attempt to avert a no-deal Brexit.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.